Dale M. Watt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dale M. Watt has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Colin Nixon
Cancer Research UK Scotland Institute, Glasgow, United Kingdom
20 shared publications - Owen James Sansom
School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom
20 shared publications - Jennifer P. Morton
Preclinical Pancreatic Cancer, Cancer Research UK Scotland Institute, Glasgow, United Kingdom
19 shared publications - William Clark
Cancer Research UK Scotland Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK
19 shared publications - Andrew D. Campbell
Cancer Research UK Scotland Institute, Glasgow, United Kingdom
18 shared publications - Arafath Kaja Najumudeen
Cancer Research UK Scotland Institute, Glasgow, UK
18 shared publications
Latest Publications
- Open Access
Cholesterol and p53 promote senescence and systemic fibrosis in metabolic dysfunction-associated steatohepatitis
Background & aims: TP53 (p53) coordinates diverse cellular stress response programmes including pro-survival activities, senescence, and cell death. During tissue damage, p53 can shape both the local cellular response to injury, including the fibrotic response, and influence distal organ biology. Fibrosis in the liver is a major driver of hepatocellular carcinoma (HCC) risk within metabolic dysfunction-associated steatohepatitis (MASH). It is also an important determinant of dysfunction in multiple distal tissues including the kidneys, lungs, and heart. Despite significant clinical burden, our understanding of the molecular determinants of fibrotic MASH and its relationship to multiorgan fibrosis remain incomplete. Here, we investigate local and systemic effects of hepatocellular p53 activity and cholesterol during MASH development, with implications for disease prevention. Methods: This study utilised a genetic model of stabilised p53, diet-induced MASH models with varying cholesterol compositions, and an in vitro obesogenic system to investigate p53 activity during liver disease development. Non-invasive imaging and histopathological analyses were employed to monitor p53 activity, MASH, and multiorgan fibrosis in vivo . Complementary approaches, including in vitro human multicomponent liver spheroids, cytokine arrays, and analyses of human MASH transcriptomic and proteomic datasets, were used to examine molecular drivers and patient relevance. Results: Using an inducible mouse model of MDM2 E3 ubiquitin ligase deficiency to stabilise p53, we report that hepatocellular MDM2 E3 loss results in progressive fibrotic damage, robust hepatocellular expression of the p53 target gene CDKN1A/p21 (p21),and induces p21 and fibrosis in the kidneys of male mice in a sex-specific manner. In diet-induced MASH, we observe cholesterol and p53-dependent development of liver fibrosis, high expression of hepatocellular p21, and induction of p21 and fibrosis in the kidneys of male mice—reminiscent of features observed in MDM2 E3-deficient mice. We also observe fibrosis in the lungs and heart of male MASH mice. Both a cholesterol-free obesogenic diet and liver-specific loss of p53 mitigate hepatic fibrosis and systemic induction of p21 and fibrosis. Mechanistically, p53 induces hepatic expression of senescence-associated secretory phenotype (SASP) factors, including GDF15, in vivo . A human multicomponent LiverACE spheroid model showed a concordant trend towards increased GDF15 protein abundance under steatotic stress, while in humans, elevated circulating GDF15 levels in advanced MASH correlate with increased TNFRSF1A and EPHA2, circulating markers linked to kidney injury. Conclusions: Our work identifies undue p53 activity within the liver as a driver of multiorgan fibrosis in a sex-specific manner, affecting male but not female mice. We implicate cholesterol in promoting this pro-fibrotic environment in vivo and highlight circulating factors that could identify at-risk patients for multiorgan fibrosis in MASH. IMPACT AND IMPLICATIONS: P53 is a potent tumour suppressor that is frequently mutated or lost in HCC. Our findings suggest that dietary cholesterol promotes detrimental overactivation of p53 in MASH and facilitates fibrosis within the liver and distal organs. Further studies evaluating the efficacy of targeting hepatic p53 in combination with dietary or weight loss interventions could provide new treatment approaches for systemic fibrosis and MASH.
Open AccessCholesterol and p53 promote senescence and systemic fibrosis in metabolic dysfunction-associated steatohepatitis
Background & aims: TP53 (p53) coordinates diverse cellular stress response programmes including pro-survival activities, senescence, and cell death. During tissue damage, p53 can shape both the local cellular response to injury, including the fibrotic response, and influence distal organ biology. Fibrosis in the liver is a major driver of hepatocellular carcinoma (HCC) risk within metabolic dysfunction-associated steatohepatitis (MASH). It is also an important determinant of dysfunction in multiple distal tissues including the kidneys, lungs, and heart. Despite significant clinical burden, our understanding of the molecular determinants of fibrotic MASH and its relationship to multiorgan fibrosis remain incomplete. Here, we investigate local and systemic effects of hepatocellular p53 activity and cholesterol during MASH development, with implications for disease prevention. Methods: This study utilised a genetic model of stabilised p53, diet-induced MASH models with varying cholesterol compositions, and an in vitro obesogenic system to investigate p53 activity during liver disease development. Non-invasive imaging and histopathological analyses were employed to monitor p53 activity, MASH, and multiorgan fibrosis in vivo . Complementary approaches, including in vitro human multicomponent liver spheroids, cytokine arrays, and analyses of human MASH transcriptomic and proteomic datasets, were used to examine molecular drivers and patient relevance. Results: Using an inducible mouse model of MDM2 E3 ubiquitin ligase deficiency to stabilise p53, we report that hepatocellular MDM2 E3 loss results in progressive fibrotic damage, robust hepatocellular expression of the p53 target gene CDKN1A/p21 (p21),and induces p21 and fibrosis in the kidneys of male mice in a sex-specific manner. In diet-induced MASH, we observe cholesterol and p53-dependent development of liver fibrosis, high expression of hepatocellular p21, and induction of p21 and fibrosis in the kidneys of male mice—reminiscent of features observed in MDM2 E3-deficient mice. We also observe fibrosis in the lungs and heart of male MASH mice. Both a cholesterol-free obesogenic diet and liver-specific loss of p53 mitigate hepatic fibrosis and systemic induction of p21 and fibrosis. Mechanistically, p53 induces hepatic expression of senescence-associated secretory phenotype (SASP) factors, including GDF15, in vivo . A human multicomponent LiverACE spheroid model showed a concordant trend towards increased GDF15 protein abundance under steatotic stress, while in humans, elevated circulating GDF15 levels in advanced MASH correlate with increased TNFRSF1A and EPHA2, circulating markers linked to kidney injury. Conclusions: Our work identifies undue p53 activity within the liver as a driver of multiorgan fibrosis in a sex-specific manner, affecting male but not female mice. We implicate cholesterol in promoting this pro-fibrotic environment in vivo and highlight circulating factors that could identify at-risk patients for multiorgan fibrosis in MASH. IMPACT AND IMPLICATIONS: P53 is a potent tumour suppressor that is frequently mutated or lost in HCC. Our findings suggest that dietary cholesterol promotes detrimental overactivation of p53 in MASH and facilitates fibrosis within the liver and distal organs. Further studies evaluating the efficacy of targeting hepatic p53 in combination with dietary or weight loss interventions could provide new treatment approaches for systemic fibrosis and MASH.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Loss of wild-type KRAS sensitizes KPC KrasG12D/fl tumours to MEK1/2 inhibition.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Loss of wild-type KRAS sensitizes KPC KrasG12D/fl tumours to MEK1/2 inhibition.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Acceleration of pancreatic tumour initiation after loss of wild-type Kras in KPC KrasG12D/fl mice.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Acceleration of pancreatic tumour initiation after loss of wild-type Kras in KPC KrasG12D/fl mice.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Release from AZD6244 treatment results in rapid acinar to ductal metaplasia in KC KrasG12D/fl.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Release from AZD6244 treatment results in rapid acinar to ductal metaplasia in KC KrasG12D/fl.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Increased fibrosis in wild-type Kras deficient PanINs.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Increased fibrosis in wild-type Kras deficient PanINs.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
MEK1/2 inhibition in KPC KrasG12D/fl mice with established tumours reverses enrichment of immune response related gene programmes.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
MEK1/2 inhibition in KPC KrasG12D/fl mice with established tumours reverses enrichment of immune response related gene programmes.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Loss of wild-type KRAS does not alter PI3K-AKT signalling.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Loss of wild-type KRAS does not alter PI3K-AKT signalling.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Loss of WT Kras increases PanIN formation in the presence of oncogenic Kras. A, Kaplan–Meier survival curve for human patients with PDAC with KRAS alleles balanced and KRAS alleles imbalanced. KRAS balanced, n = 47; KRAS imbalanced, n = 32. *, P = 0.029, log-rank (Mantel–Cox) test. B, Proportion of human patients with pancreatic cancer with KRAS alleles balanced (59.5%) and KRAS alleles imbalanced (40.5%), from A. C, Schematic representing generation of KC KrasG12D/fl mice. D, Representative hematoxylin and eosin (H&E) images of pancreata from KC KrasG12D/+ and KC KrasG12D/fl mice at 42 days of age, representative of six mice per group. Scale bar, 200 μm. E, Quantification and grading of PanINs from KC KrasG12D/+ and KC KrasG12D/fl mice at 42 days of age from one whole hematoxylin and eosin section per mouse (n = 6 per group), represented by D. Boxes depict the IQR, the central line indicates the median, and whiskers indicate minimum/maximum values. **, P < 0.01; one-way Mann–Whitney U test. F, Quantification of the area of ADM per mm2 pancreas over one whole hematoxylin and eosin section from KC KrasG12D/+ and KC KrasG12D/fl mice at 42 days of age (n = 6 per group). Boxes depict the IQR, the central line indicates the median, and whiskers indicate minimum/maximum values. **, P < 0.0011; one-way Mann–Whitney U test. G, Left, representative IHC images of pERK1/2 of pancreata from KC KrasG12D/+ and KC KrasG12D/fl mice at 42 days of age. Representative of six mice per group. Scale bar, 200 μm. Right, bar graphs showing quantification of pERK1/2-positive cells of the pancreatic epithelium of KC KrasG12D/+ and KC KrasG12D/fl mice sampled at day 42 (KC KrasG12D/+, n = 6; KC KrasG12D/fl, n = 6). Data are the mean ± SEM. *, P = 0.0325; one-way Mann–Whitney U test. H, Left, representative images of ISH of Dusp5 and Dusp6 of pancreata from KC KrasG12D/+ and KC KrasG12D/fl mice at 42 days of age. Representative of six mice per group. Scale bar, 200 μm. Right, quantification of Dusp5 and Dusp6 ISH staining of pancreatic lesions (PanINs) of pancreata from KC KrasG12D/+ and KC KrasG12D/fl mice at 42 days of age (KC KrasG12D/+, n = 6; KC KrasG12D/fl, n = 6). Data are the mean ± SEM. **, P = 0.0011 (Dusp5); **, P = 0.0022 (Dusp6); one-way Mann–Whitney U test. Cre, Cre recombinase; loxP, Cre-loxP recombination site.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Loss of WT Kras increases PanIN formation in the presence of oncogenic Kras. A, Kaplan–Meier survival curve for human patients with PDAC with KRAS alleles balanced and KRAS alleles imbalanced. KRAS balanced, n = 47; KRAS imbalanced, n = 32. *, P = 0.029, log-rank (Mantel–Cox) test. B, Proportion of human patients with pancreatic cancer with KRAS alleles balanced (59.5%) and KRAS alleles imbalanced (40.5%), from A. C, Schematic representing generation of KC KrasG12D/fl mice. D, Representative hematoxylin and eosin (H&E) images of pancreata from KC KrasG12D/+ and KC KrasG12D/fl mice at 42 days of age, representative of six mice per group. Scale bar, 200 μm. E, Quantification and grading of PanINs from KC KrasG12D/+ and KC KrasG12D/fl mice at 42 days of age from one whole hematoxylin and eosin section per mouse (n = 6 per group), represented by D. Boxes depict the IQR, the central line indicates the median, and whiskers indicate minimum/maximum values. **, P < 0.01; one-way Mann–Whitney U test. F, Quantification of the area of ADM per mm2 pancreas over one whole hematoxylin and eosin section from KC KrasG12D/+ and KC KrasG12D/fl mice at 42 days of age (n = 6 per group). Boxes depict the IQR, the central line indicates the median, and whiskers indicate minimum/maximum values. **, P < 0.0011; one-way Mann–Whitney U test. G, Left, representative IHC images of pERK1/2 of pancreata from KC KrasG12D/+ and KC KrasG12D/fl mice at 42 days of age. Representative of six mice per group. Scale bar, 200 μm. Right, bar graphs showing quantification of pERK1/2-positive cells of the pancreatic epithelium of KC KrasG12D/+ and KC KrasG12D/fl mice sampled at day 42 (KC KrasG12D/+, n = 6; KC KrasG12D/fl, n = 6). Data are the mean ± SEM. *, P = 0.0325; one-way Mann–Whitney U test. H, Left, representative images of ISH of Dusp5 and Dusp6 of pancreata from KC KrasG12D/+ and KC KrasG12D/fl mice at 42 days of age. Representative of six mice per group. Scale bar, 200 μm. Right, quantification of Dusp5 and Dusp6 ISH staining of pancreatic lesions (PanINs) of pancreata from KC KrasG12D/+ and KC KrasG12D/fl mice at 42 days of age (KC KrasG12D/+, n = 6; KC KrasG12D/fl, n = 6). Data are the mean ± SEM. **, P = 0.0011 (Dusp5); **, P = 0.0022 (Dusp6); one-way Mann–Whitney U test. Cre, Cre recombinase; loxP, Cre-loxP recombination site.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Loss of WT KRAS induces increased MAPK signaling in KPC KrasG12D/fl. A, Experimental schematic representing mice imaged once weekly by ultrasound from 6 weeks of age to clinical endpoint to follow tumor growth over time. B, Tumor volume relative to that of tumor at initial detection from KPC KrasG12D/+ and KPC KrasG12D/fl mice aged to clinical endpoint and measured once weekly by ultrasound imaging from 6 weeks of age. KPC KrasG12D/fl, n = 8; KPC KrasG12D/+, n = 10. FC, fold change. C, Kaplan–Meier survival curves for KPC KrasG12D/+ and KPC KrasG12D/fl mice aged to clinical endpoint. KPC KrasG12D/fl, n = 29; KPC KrasG12D/+, n = 23. *, P = 0.0396 log-rank (Mantel–Cox) test. Mice were censored when reaching clinical endpoint not associated with PDAC burden, such as primary tumors, which arose from other tissue, mostly mucocutaneous papillomas or lymphomas (typically thymic) but also gastric and lung tumors. MS, median survival. D, Incidence of metastasis (%) in KPC KrasG12D/+ and KPC KrasG12D/fl mice. KPC KrasG12D/fl, n = 27; KPC KrasG12D/+, n = 20. mets, metastasis. E, Migration speed of established cell lines derived from pancreatic cancers arising in KPC KrasG12D/+ and KPC KrasG12D/fl mice. F, Relative probe intensity in ddPCR from tumors arising in KPC KrasG12D/+ (n = 16) and KPC KrasG12D/fl (n = 9) mice at clinical endpoint, comparing KrasG12D to KrasWT and KrasG12D to Gapdh probe sets. Tumors from which cell lines analyzed in I were generated are highlighted in this analysis. G, Representative IHC images of CD3, CD4, and CD8a from PDAC arising in KPC KrasG12D/+ and KPC KrasG12D/fl mice taken at clinical endpoint. Representative of five mice per group. Scale bar, 200 μm. H, Bar graphs showing quantification of proportion of CD3-, CD4-, and CD8a-positive cells in PDAC tissue from KPC KrasG12D/+ and KPC KrasG12D/fl mice sampled at clinical endpoint (KPC KrasG12D/+, n = 5; KPC KrasG12D/fl, n = 5). Data are the mean ± SEM, represented in G. I, Immunoblotting of pMEK1/2, MEK1/2, pERK1/2, ERK1/2, and KrasG12D of KPC KrasG12D/+ and KPC KrasG12D/fl PDAC tissue lysates generated from mice at clinical endpoint. β-Actin was used as a loading control. Each lane represents PDAC tissue from an individual mouse of the indicated genotype. Bar graph shows quantification of pMEK1/2 levels, normalized to MEK1/2; pERK1/2 levels, normalized to ERK1/2; and KRAS-G12D levels, normalized to β-actin. Data represent the mean ± SEM. *, P = 0.0143; one-way Mann–Whitney U test. J, qRT-PCR analysis of Etv4, Etv5, Dusp4, Dusp6, Spry1, and Spry2 in KPC KrasG12D/+ and KPC KrasG12D/fl PDAC tissue. Transcript levels were normalized to Gapdh (KPC KrasG12D/+, n = 5; KPC KrasG12D/fl, n = 6). Data represent the mean ± SEM. P = 0.2 (Etv4); **, P = 0.0087 (Etv5); P = 0.4 (Dusp4); **, P = 0.0087 (Dusp6); *, P = 0.0152 (Spry1); and *, P = 0.0411 (Spry2); ns, nonsignificant; one-way Mann–Whitney U test. Rel., relative.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Loss of WT KRAS induces increased MAPK signaling in KPC KrasG12D/fl. A, Experimental schematic representing mice imaged once weekly by ultrasound from 6 weeks of age to clinical endpoint to follow tumor growth over time. B, Tumor volume relative to that of tumor at initial detection from KPC KrasG12D/+ and KPC KrasG12D/fl mice aged to clinical endpoint and measured once weekly by ultrasound imaging from 6 weeks of age. KPC KrasG12D/fl, n = 8; KPC KrasG12D/+, n = 10. FC, fold change. C, Kaplan–Meier survival curves for KPC KrasG12D/+ and KPC KrasG12D/fl mice aged to clinical endpoint. KPC KrasG12D/fl, n = 29; KPC KrasG12D/+, n = 23. *, P = 0.0396 log-rank (Mantel–Cox) test. Mice were censored when reaching clinical endpoint not associated with PDAC burden, such as primary tumors, which arose from other tissue, mostly mucocutaneous papillomas or lymphomas (typically thymic) but also gastric and lung tumors. MS, median survival. D, Incidence of metastasis (%) in KPC KrasG12D/+ and KPC KrasG12D/fl mice. KPC KrasG12D/fl, n = 27; KPC KrasG12D/+, n = 20. mets, metastasis. E, Migration speed of established cell lines derived from pancreatic cancers arising in KPC KrasG12D/+ and KPC KrasG12D/fl mice. F, Relative probe intensity in ddPCR from tumors arising in KPC KrasG12D/+ (n = 16) and KPC KrasG12D/fl (n = 9) mice at clinical endpoint, comparing KrasG12D to KrasWT and KrasG12D to Gapdh probe sets. Tumors from which cell lines analyzed in I were generated are highlighted in this analysis. G, Representative IHC images of CD3, CD4, and CD8a from PDAC arising in KPC KrasG12D/+ and KPC KrasG12D/fl mice taken at clinical endpoint. Representative of five mice per group. Scale bar, 200 μm. H, Bar graphs showing quantification of proportion of CD3-, CD4-, and CD8a-positive cells in PDAC tissue from KPC KrasG12D/+ and KPC KrasG12D/fl mice sampled at clinical endpoint (KPC KrasG12D/+, n = 5; KPC KrasG12D/fl, n = 5). Data are the mean ± SEM, represented in G. I, Immunoblotting of pMEK1/2, MEK1/2, pERK1/2, ERK1/2, and KrasG12D of KPC KrasG12D/+ and KPC KrasG12D/fl PDAC tissue lysates generated from mice at clinical endpoint. β-Actin was used as a loading control. Each lane represents PDAC tissue from an individual mouse of the indicated genotype. Bar graph shows quantification of pMEK1/2 levels, normalized to MEK1/2; pERK1/2 levels, normalized to ERK1/2; and KRAS-G12D levels, normalized to β-actin. Data represent the mean ± SEM. *, P = 0.0143; one-way Mann–Whitney U test. J, qRT-PCR analysis of Etv4, Etv5, Dusp4, Dusp6, Spry1, and Spry2 in KPC KrasG12D/+ and KPC KrasG12D/fl PDAC tissue. Transcript levels were normalized to Gapdh (KPC KrasG12D/+, n = 5; KPC KrasG12D/fl, n = 6). Data represent the mean ± SEM. P = 0.2 (Etv4); **, P = 0.0087 (Etv5); P = 0.4 (Dusp4); **, P = 0.0087 (Dusp6); *, P = 0.0152 (Spry1); and *, P = 0.0411 (Spry2); ns, nonsignificant; one-way Mann–Whitney U test. Rel., relative.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Pancreatic cancer is characterized by the prevalence of oncogenic mutations in KRAS. Previous studies have reported that altered KRAS gene dosage drives progression and metastasis in pancreatic cancer. Whereas the role of oncogenic KRAS mutations is well characterized, the relevance of the partnering wild-type (WT) KRAS allele in pancreatic cancer is less well understood and controversial. Using in vivo mouse modeling of pancreatic cancer, we demonstrated that WT KRAS restrains the oncogenic impact of mutant KRAS and dramatically impacts both KRAS-mediated tumorigenesis and therapeutic response. Mechanistically, deletion of WT Kras increased oncogenic KRAS signaling through the downstream MAPK effector pathway, driving pancreatic intraepithelial neoplasia initiation. In addition, in the KPC mouse model, a more aggressive model of pancreatic cancer, lack of WT KRAS led to accelerated initiation but delayed tumor progression. These tumors had altered stroma and an enrichment of immunogenic gene signatures. Importantly, loss of WT Kras sensitized Kras mutant tumors to MEK1/2 inhibition though tumors eventually became resistant and then rapidly progressed. This study demonstrates the repressive role of WT KRAS during pancreatic tumorigenesis and highlights the critical impact of the presence of WT KRAS in both tumor progression and therapeutic response in pancreatic cancer.Significance:KRAS allelic status impacts pancreatic cancer progression and has the potential to guide effective treatment in a substantial subset of patients.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Pancreatic cancer is characterized by the prevalence of oncogenic mutations in KRAS. Previous studies have reported that altered KRAS gene dosage drives progression and metastasis in pancreatic cancer. Whereas the role of oncogenic KRAS mutations is well characterized, the relevance of the partnering wild-type (WT) KRAS allele in pancreatic cancer is less well understood and controversial. Using in vivo mouse modeling of pancreatic cancer, we demonstrated that WT KRAS restrains the oncogenic impact of mutant KRAS and dramatically impacts both KRAS-mediated tumorigenesis and therapeutic response. Mechanistically, deletion of WT Kras increased oncogenic KRAS signaling through the downstream MAPK effector pathway, driving pancreatic intraepithelial neoplasia initiation. In addition, in the KPC mouse model, a more aggressive model of pancreatic cancer, lack of WT KRAS led to accelerated initiation but delayed tumor progression. These tumors had altered stroma and an enrichment of immunogenic gene signatures. Importantly, loss of WT Kras sensitized Kras mutant tumors to MEK1/2 inhibition though tumors eventually became resistant and then rapidly progressed. This study demonstrates the repressive role of WT KRAS during pancreatic tumorigenesis and highlights the critical impact of the presence of WT KRAS in both tumor progression and therapeutic response in pancreatic cancer.Significance:KRAS allelic status impacts pancreatic cancer progression and has the potential to guide effective treatment in a substantial subset of patients.